1. Cifuentes, Claudia, Oeste, Clara L, Fernández-Pisonero, Isabel, Bustelo, Xosé R, Alarcón, Balbino. 2024. Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer. In Molecular cancer, 23, 142. doi:10.1186/s12943-024-02054-3. https://pubmed.ncbi.nlm.nih.gov/38987766/
2. Hortal, Alejandro M, Oeste, Clara L, Cifuentes, Claudia, González, Marcos, Alarcón, Balbino. 2022. Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. In Molecular cancer, 21, 35. doi:10.1186/s12943-022-01496-x. https://pubmed.ncbi.nlm.nih.gov/35120522/
3. Yu, Chaonan, Lyn, Nan, Li, Dongxiao, Liu, Lei, Shang, Qing. 2022. Clinical analysis of Noonan syndrome caused by RRAS2 mutations and literature review. In European journal of medical genetics, 66, 104675. doi:10.1016/j.ejmg.2022.104675. https://pubmed.ncbi.nlm.nih.gov/36460282/
4. Wang, Kejun, Peng, Kan. . RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway. In Anti-cancer drugs, 30, 933-939. doi:10.1097/CAD.0000000000000799. https://pubmed.ncbi.nlm.nih.gov/31517733/